A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Status unconfirmed · Phase 1/Phase 2
Conditions studied: Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
In brief
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Key facts
- Study ID
- NCT04903873
- Run by
- Eutilex
- People needed
- 110
- Starts
- 2021-05-31
- Expected to finish
- 2025-12-01
- Last updated by the study team
- 2024-03-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- Mary Crowley Center — Dallas, Texas, United States (enrolling)
- Samsung Seoul Hospital — Seoul, South Korea (enrolling)
- Seoul Asan — Seoul, South Korea (enrolling)
- Severance Hospital — Seoul, South Korea (enrolling)
- National Cancer Center — Ilsan, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.